Circulating tumor DNA and homologous recombination deficiency in bone-predominant mCRPC prior to radium-223 therapy

Targeted sequencing with ctDNA identified HRD positivity among patients with bone-predominant metastatic castration-resistant prostate cancer—prior to receiving radium-223 treatment—and low median tumor fraction at a similar frequency as prior tissue-based assays, according to data presented during the 2023 ASCO Genitourinary Cancers Symposium.